Toludesvenlafaxine hydrochloride sustained-release tablets
Sponsors
Shanghai Mental Health Center, Jiangsu Province Nanjing Brain Hospital, First Affiliated Hospital of Zhejiang University, Luye Pharma Group Ltd.
Conditions
AnhedoniaMajor Depression DisorderMajor Depressive DisorderSomatic Symptom
Phase 4
Efficacy and Safety of Toluedesvenlafaxine Hydrochloride Extended-release Tablets in Somatic Symptoms of Depression
CompletedNCT05849272
Start: 2023-05-12End: 2024-05-08Updated: 2025-05-31
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
NCT06026917
Start: 2023-09-25End: 2024-03-31Target: 15Updated: 2023-10-19
To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets
Not yet recruitingNCT06426485
Start: 2024-05-30End: 2027-06-30Target: 736Updated: 2024-05-23
Unknown Phase
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder
RecruitingNCT06270433
Start: 2024-02-19End: 2024-12-31Target: 80Updated: 2024-04-29
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder
CompletedNCT06278038
Start: 2024-02-22End: 2024-11-19Updated: 2025-04-01